Efficacy of ofloxacin and other ototopical preparations for chronic suppurative otitis media in children.
The safety and efficacy of ototopical preparations, such as ofloxacin, in the treatment of CSOM in infants and children do not currently have approval by the FDA even though ofloxacin is FDA-approved for treatment of CSOM that occurs in adults. However, treatment with ofloxacin is FDA-approved when AOM occurs in children who have a tympanostomy tube in place, and effective treatment of this acute infection should prevent the subsequent development of CSOM.
Bluestone
C D
CD
University of Pittsburgh School of Medicine, and the Department of Pediatrics Otolaryngology, Children's Hospital of Pittsburgh, PA 15213, USA. Bluestc@chplink.chp.edu
D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000891:Anti-Infective Agents, Local / Q000494:pharmacology / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects*; D002648:Child; D002908:Chronic Disease; D006801:Humans; D008876:Middle Ear Ventilation; D015242:Ofloxacin / Q000627:therapeutic use*; D010035:Otitis Media, Suppurative / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D012449:Safety; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D000890:Anti-Infective Agents; D000891:Anti-Infective Agents, Local; D015242:Ofloxacin